European Society for Medical Oncology Advanced Course on Deep Dive in CDK4-6 Inhibitors Data in Breast Cancer Dubai 2023

20 $

+ Include: 9 videos + 10 pdfs, size: 7.58 GB

+ Target Audience: oncologist

Description

+ Include: 9 videos + 10 pdfs, size: 7.58 GB

+ Target Audience: oncologist

+ Sample video: contact me for sample video

+ Information:

Start date 20 May 2023
End date 20 May 2023
Location Dubai, United Arab Emirates

Learning objectives

  • Understanding the function and biology of CDK4-6 in malignant breast cancer cells
  • Information and in-depth discussion on the state of the art and emerging therapeutic strategies integrating CDK4-6 inhibition in breast cancer, both in the metastatic setting
  • Presenting novel data on biomarkers of benefit, mechanisms of resistance and combinatorial therapeutic strategies of CDK4-6 inhibition
  • Providing an outlook of potential integration of CDK 4-6 inhibitors in the adjuvant setting
  • Discussing clinical cancer cases to integrate use of CDK 4-6 inhibitors in clinical practice

 

 

 

+ Topics:

Programme.pdf
Session 1 Cont Clinical cases of high-risk patients with early HR positive HER2 negative breast cancer candidate to adjuvant CDK4-6 inhibitors Balancing efficacy and toxicity.mp4
Session 1 Cont Clinical cases of high-risk patients with early HR positive HER2 negative breast cancer candidate to adjuvant CDK4-6 inhibitors Balancing efficacy and toxicity.pdf
Session 1 Integrating CDK4-6 inhibitors in patients with early HR positive HER2 negative breast cancer Successes and failures.mp4
Session 1 Integrating CDK4-6 inhibitors in patients with early HR positive HER2 negative breast cancer Successes and failures.pdf
Session 1 Ongoing clinical studies on CDK4-6 inhibition in early HR positive HER2 negative breast cancer.mp4
Session 1 Ongoing clinical studies on CDK4-6 inhibition in early HR positive HER2 negative breast cancer.pdf
Session 1 Risk stratification in HR positive HER2 negative early breast cancer Lessons from neoadjuvant and adjuvant setting.mp4
Session 1 Risk stratification in HR positive HER2 negative early breast cancer Lessons from neoadjuvant and adjuvant setting.pdf
Session 2 CDK4-6 inhibition in patients with metastatic HR positive HER2 negative breast cancer Benefit in endocrine resistant disease.mp4
Session 2 CDK4-6 inhibition in patients with metastatic HR positive HER2 negative breast cancer Benefit in endocrine resistant disease.pdf
Session 2 Emerging data on new agents and new combinations in endocrine resistant disease.mp4
Session 2 Emerging data on new agents and new combinations in endocrine resistant disease.pdf
Session 3 CDK4-6 inhibitors beyond CDK4-6 inhibitors in metastatic setting.mp4
Session 3 CDK4-6 inhibitors beyond CDK4-6 inhibitors in metastatic setting.pdf
Session 3 Role of CD 4-6 inhibitors across enriched molecular subgroup.mp4
Session 3 Role of CD 4-6 inhibitors across enriched molecular subgroup.pdf
Welcome and introduction.mp4
Welcome and introduction.pdf

Reviews

There are no reviews yet.

Be the first to review “European Society for Medical Oncology Advanced Course on Deep Dive in CDK4-6 Inhibitors Data in Breast Cancer Dubai 2023”

Your email address will not be published. Required fields are marked *